DIFFERENTIAL G PROTEIN ACTIVATION BY ISOFORMS OF THE DOPAMINE D2 RECEPTOR
Main Article Content
Keywords
iso-form, receptors, cell types
Abstract
The dopamine D2 receptor is expressed as a short (D2S) and a long (D2L) isoform with 29 additional amino acids in the third intracellular loop. The D2S isoform shows higher presynaptic expression than the D2L isoform, and decreased D2S expression has recently been linked to an increased risk for schizophrenia. Here, we present the first investigation, at receptor isoform level, of kinetic differences in the G protein activation profiles of the D2S, compared with the D2L isoform.
Experimental Approach
We employed a NanoBRET-based approach to G protein dissociation to interrogate the time-resolved coupling profile of 3×HA-tagged D2L and D2S to Gαi/o/z proteins in vitro.
Key Results
Using dopamine as a D2 receptor agonist, we observed a more pronounced activation of Gαo and Gαz than Gαi proteins by D2L compared with D2S. This differentiation was not observed for D2S, which activated Gαo and Gαz with lower efficacy than D2L. These signalling differences were preserved on second messenger level and were not due to differences in receptor expression. Expanding to a set of seven full and partial D2 receptor agonists showed these effects were not restricted to dopamine but rather a mutual, receptor-associated property. Contrasting this trend, we found that D2S activated G proteins faster than D2L upon full receptor activation.
Conclusion and Implications
The findings highlight that both D2L and D2S are mechanistically able to activate all non-visual Gαi/o proteins. Thereby, they add to previous reports about isoform-specificity to certain Gαi/o proteins observed in specific cell types.
References
2. Bauer ME, MacBrayne C, Stein A, et al. A multidisciplinary quality improvement initiative to facilitate penicillin al- lergy delabeling among hospitalized pediatric patients. Hosp Peds. 2021;11(5):427–434.
3. Vyles D, Chiu A, Routes J, et al. Oral amoxicillin challenges in low-risk children during a pediatric emergency department visit. J Allergy Clin Immunol Pract. 2020;8(3):1126–1128.
4. Kuruvilla M, Shih J, Patel K, et al. Direct oral amoxicillin challenge without preliminary skin testing in adult pa- tients with allergy and at low risk with reported penicillin allergy. Allergy Asthma Proc. 2019;40(1):57–61.
5. Tucker MH, Lomas CM, Ramchandar N, et al. Amoxicillin challenge without penicillin skin testing in evaluation of penicillin allergy in a cohort of Marine recruits. J Allergy Clin Immunol Pract. 2017;5(3):813–815.
6. Macy E, Contreras R. Health care use and serious in- fection prevalence associated with penicillin “allergy” in hospitalized patients: a cohort study. J Allergy Clin Immunol Pract. 2014;133(3):790–796.
7. Macy E, Vyles D. Who needs penicillin allergy testing? Ann Allergy Asthma Immunol. 2018;121(5):523–529.
8. Gateman DP, Rumble JE, Protudjer JLP, et al. Amoxicil- lin oral provocation challenge in a primary care clinic: a descriptive analysis. CMAJ Open. 2021;9(2):E394–E399.
9. Mill C, Primeau M, Medoff E, et al. Assessing the diagnostic properties of a graded oral provocation challenge for the diagnosis of immediate and nonimmediate reactions to amoxicillin in children. JAMA Pediatr. 2016;170(6):e160033.
10. Stone CA, Trubiano J, Coleman DT, et al. The challenge of de-labeling penicillin allergy. Allergy. 2019;75(2):273–288.
11. Macy E, McCormick TA, Adams JL, et al. Association be- tween removal of a warning against cephalosporin use in patients with penicillin allergy and antibiotic prescribing. JAMA Netw Open. 2021;4(4):e218367.
12. Jeimy S, Ben-Shoshan M, Abrams EM, et al. Practical Guide for Evaluation and Management of Beta-Lactam Allergy: Position Statement from the Canadian Society of Allergy and Clinical Immunology. Allergy Asthma Clin Immunol. 2020;16(1):95.
13. Steenvoorden L, Bjoernestad EO, Kvesetmoen TA, et al. De-labelling penicillin allergy in acutely hospitalized patients: a pilot study. BMC Infect Dis. 2021;21(1):1083.
14. Jones TW, Fino N, Olson J, et al. The impact of beta- lactam allergy labels on hospitalized children. Infect Control Hosp Epidemiol. 2020;42(3):318–324.
15. Antoon JW, Grijalva CG, Grisso AG, et al. Feasibility of a centralized, pharmacy-led penicillin allergy delabeling program. Hosp Pediatr. 2022;12(7):e230–237.
16. Iammatteo M, Alvarez Arango S, Ferastraoaru D, et al. Safety and outcomes of oral graded challenges to amoxi- cillin without prior skin testing. J Allergy Clin Immunol Pract. 2019;7(1):236–243.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr ashutosh gupta
Assistant professor , department of pharmacology , career institute of medical sciences and hospital
Dr Abhay joshi
Assistant professor, department of pharmacology, career institute of medical sciences and hospital